trending Market Intelligence /marketintelligence/en/news-insights/trending/mw7A5Yuv68Etj3nA7iOfOA2 content esgSubNav
In This List

Biotricity's remote heart disease monitoring device secures US FDA clearance

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Biotricity's remote heart disease monitoring device secures US FDA clearance

The U.S. Food and Drug Administration granted 510(k) clearance to Biotricity Inc.'s Bioflux device.

Bioflux consists of a proprietary mobile electrocardiography or ECG monitoring device and an ECG viewer software package that enables physicians to remotely monitor and diagnose patients with cardiovascular coronary heart disease.